Two phase-3 studies demonstrated that the combination of G-CSF and plerixafor is superior to G-CSF alone for mobilizing hematopoietic progenitor cells in front-line or as salvage therapy in patients with MM [11, 12]. This evidence concerns the gene CSF3 and Miyoshi myopathy.